The CEMIP (Cell Migration Inducing Protein) antibody is a research tool targeting the CEMIP protein, also known as KIAA1199 or HYBID. Initially identified for its role in cell migration and extracellular matrix remodeling, CEMIP gained attention due to its overexpression in cancers, including colorectal, breast, and prostate tumors, where it promotes metastasis, angiogenesis, and therapy resistance. CEMIP regulates hyaluronan degradation, activates pro-inflammatory pathways (e.g., NF-κB), and interacts with Wnt/β-catenin signaling, contributing to tumor progression. Beyond oncology, CEMIP is implicated in osteoarthritis and age-related disorders linked to tissue remodeling. Antibodies against CEMIP are used to study its expression patterns, subcellular localization, and functional mechanisms in disease models. They also hold potential as diagnostic biomarkers or therapeutic agents, with efforts underway to develop blocking antibodies or CAR-T cells targeting CEMIP-positive cancers. However, challenges remain in understanding isoform-specific roles and ensuring antibody specificity, given CEMIP's complex post-translational modifications. Current research focuses on validating its clinical utility and exploring its broader pathophysiological relevance.